Objective: To assess the clinimetric properties of the Hebrew version of the UDysRS.

Background: Dyskinesia is a common side effect of dopaminergic treatments for Parkinson’s disease (PD). The Unified Dyskinesia Rating Scale (UDysRS) was developed as a comprehensive rating tool for severity and disability associated with dyskinesia in patients with PD. The scale was developed in English with a clinimetric program to provide validated non‐English translations.

Method: The UDysRS was translated into Hebrew, back-translated, cognitively pre-tested and then tested in non-demented native-Hebrew speaking PD patients.    Floor and ceiling effects and internal consistency of the translated scale were examined.  Factor validity was tested against the Spanish version of the UDysRS, which is considered to be the “Reference  MDS Translation” of the original English version, using the Comparative Fit Index (CFI) based on confirmatory factor analysis techniques. A secondary analysis included an exploratory factor analysis (EFA) to explore factor structure.

Results: The study population included 250 patients, 66.4% males (mean age 68.5±8.8). Disease duration (y) was 11.8±6.7 out of which dyskinesia was present for 6.7±5.4 years. Floor and ceiling effects were negligible. The internal consistency of the Hebrew-version was, with Cronbach’s alpha value of 0.96. The CFI in comparison to the Spanish Language was 0.98 which corresponds to our pre-specified criterion of CFI>0.9 in order to confirm factor validity. The factor structure of Hebrew UDysRS was quite consistent with that of the Reference UDysRS.

Conclusion: The UDysRS Hebrew version shows strong clinimetric properties and may be designated as an Official MDS-Approved Translation for use in clinical and research settings.

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/validation-of-the-hebrew-version-of-the-unified-dyskinesia-rating-scale-udysrs/